These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2661281)

  • 61. Compliance in black patients with non-insulin-dependent diabetes mellitus receiving oral hypoglycaemic therapy.
    Venter HL; Joubert PH; Foukaridis GN
    S Afr Med J; 1991 May; 79(9):549-51. PubMed ID: 2024212
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Current status of prescription in type 2 diabetic patients from general hospitals in busan.
    Suk JH; Lee CW; Son SP; Kim MC; Ahn JH; Lee KJ; Park JY; Shin SH; Kwon MJ; Kim SS; Kim BH; Lee SH; Park JH; Kim IJ;
    Diabetes Metab J; 2014 Jun; 38(3):230-9. PubMed ID: 25003077
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MANAGEMENT OF TYPE 2 DIABETES (NIDDM).
    Garg MK; Baliga KV
    Med J Armed Forces India; 2002 Jan; 58(1):53-9. PubMed ID: 27365661
    [No Abstract]   [Full Text] [Related]  

  • 64. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes.
    Groop LC; Pelkonen R; Koskimies S; Bottazzo GF; Doniach D
    Diabetes Care; 1986; 9(2):129-33. PubMed ID: 3516607
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea.
    Kunavisarut T; Sriussadaporn S; Lertwattanarak R
    Diabetes Metab Syndr Obes; 2019; 12():761-770. PubMed ID: 31190934
    [No Abstract]   [Full Text] [Related]  

  • 66. Associations among body mass index, insulin resistance, and pancreatic β-cell function in Korean patients with new-onset type 2 diabetes.
    Chung JO; Cho DH; Chung DJ; Chung MY
    Korean J Intern Med; 2012 Mar; 27(1):66-71. PubMed ID: 22403502
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Parameters measuring beta-cell function are only valuable in diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes.
    Lee SW; Lee S; Kim SH; Kim TH; Kang BS; Yoo SH; Lee MK; Koh WJ; Kang WS; Kim HJ
    Yonsei Med J; 2011 Nov; 52(6):939-47. PubMed ID: 22028157
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Genetic contribution of polymorphism of the GLUT1 and GLUT4 genes to the susceptibility to type 2 (non-insulin-dependent) diabetes mellitus in different populations.
    Pontiroli AE; Capra F; Veglia F; Ferrari M; Xiang KS; Bell GI; Baroni MG; Galton DJ; Weaver JU; Hitman GA; Kopelman PG; Mohan V; Viswanathan M
    Acta Diabetol; 1996 Sep; 33(3):193-7. PubMed ID: 8904924
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Islet cell antibodies are associated with beta-cell failure also in obese adult onset diabetic patients.
    Gottsäter A; Landin-Olsson M; Lernmark A; Fernlund P; Sundkvist G
    Acta Diabetol; 1994 Dec; 31(4):226-31. PubMed ID: 7888694
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Factors for development of secondary failure to sulfonylurea drugs in non-insulin-dependent diabetes mellitus.
    Borissova AM; Koev DG; Minev MG; Martinova FG; Gencova PI; Kirilov GG; Arnaudov J
    Acta Diabetol Lat; 1991; 28(1):91-8. PubMed ID: 1862695
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A simple clinical approach to discriminate between "true" and "pseudo" secondary failure to oral hypoglycaemic agents.
    Scionti L; Misericordia P; Santucci A; Santeusanio F; Brunetti P
    Acta Diabetol; 1992; 29(1):20-4. PubMed ID: 1520901
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
    Scheen AJ; Castillo MJ; Lefèbvre PJ
    Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Secondary failure to oral hypoglycaemic agents in non-obese patients with non-insulin-dependent diabetes is related to reduced insulin release.
    Pontiroli AE; Calderara A; Maffi P; Bonisolli L; Carenini A; Piatti PM; Monti LD; Gallus G; Pozza G; Illeni MT
    Diabete Metab; 1989; 15(2):79-84. PubMed ID: 2661281
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Secondary failure of oral hypoglycaemic agents in lean patients with type 2 diabetes mellitus: insulin sensitivity, insulin response to different stimuli, and the role of cyclic-AMP.
    Pontiroli AE; Caviezel F; Alberetto M; Secchi A; Capra F; Bonisolli L; Calderara A; Pozza G
    Diabete Metab; 1992; 18(1):25-31. PubMed ID: 1314198
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes].
    Machoy M
    Ann Acad Med Stetin; 2004; 50(2):29-39. PubMed ID: 16529163
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.